Mesothelioma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BAP1 4
• PD-1 6
• TP53 0
• PD-L1 4
• YAP 0
• CDKN2A 0
• CTLA-4 2
• AXL 0
• B7-H3 0
• MDM2 0
• MET 0
• PRMT5 3
• VEGF 1
• AKT 0
• BRCA1 0
• EGFR 1
• EZH2 0
• FAK 0
• HMGB1 0
• NRF2 0
• PARP 0
• STAT3 0
• STK11 0
• TROP2 0
• AMPK 0
• ARID1A 1
• BRAF 0
• BRCA2 0
• CD30 0
• CD40 0
• CDK4/6 0
• GPC3 1
• IDH 0
• IL-17 0
• IL-6 0
• JNK 0
• LAG-3 1
• mTOR 0
• MUC1 0
• NTRK 1
• PI3K 0
• STING 0

15 of 15+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma

  Baylor College of Medicine· Houston, United States· US$663,998 awarded in fiscal year 2026· until Jul 2031

• NIH NCI · R01

  Microbial-based cancer therapy armored with membrane-bound cytokines for targeted immune modulation and safety-controlled delivery

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$669,278 awarded in fiscal year 2026· until May 2031

• NIH NCI · R37

  Proteomic determinants of response to checkpoint blockade in malignant pleural mesothelioma

  University of California Los Angeles· Los Angeles, United States· US$407,412 awarded in fiscal year 2026· until Dec 2027

• NIH NCI · R21

  Photofrin dark effects and heme oxygenase inducers as therapeutic in mesothelioma

  University of Pennsylvania· Philadelphia, United States· US$189,922 awarded in fiscal year 2026· until Dec 2026

• NIH NCI · R01

  Tuning KITv CAR T cells for the solid tumor environment

  Sloan-Kettering Inst Can Research· New York, United States· US$1,848,264 awarded in fiscal year 2026· until Jul 2029

5 of 8 running projects, newest first. Listed amounts together: US$8.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Updated 9 Oct 2026

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”Registry text, quoted unchanged. Source

• Withdrawn

  Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

  NCT05582031· Translational Research in Oncology· Updated 7 Jun 2023

  “Study never started/ will not proceed.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

  NCT07234058· Intergroupe Francophone de Cancerologie Thoracique· Source

• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

  NCT02628067· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Organoids 3
• Mendelian Randomization Analysis 1
• Gene Expression Profiling 6
• Exome Sequencing 3
• Proteomics 8
• Mass Spectrometry 3
• Flow Cytometry 6
• Immunohistochemistry 26
• Xenograft Model Antitumor Assays 21
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 3
• Machine Learning 6
• Deep Learning 1
• Cohort Studies 10
• Genome-Wide Association Study 3

• Patient-Derived Organoid Models and Precision HIPEC in Diffuse Malignant Peritoneal Mesothelioma: Modeling Heterogeneity to Address Recurrence.

  Int J Mol Sci, Sept 2026

• Proof-of-concept study in patient-derived organoids from malignant pleural effusion for functional testing in thoracic tumors.

  Biomed Pharmacother, Aug 2026

• A novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing.

  Sci Rep, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.